Adaptive Biotechnologies (ADPT) Assets Average (2019 - 2026)

Adaptive Biotechnologies has reported Assets Average for 8 years, with the latest figure at $509.3 million in Q1 2026.

• Quarterly Assets Average fell 3.0% year-over-year to $509.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $509.3 million (down 3.0% YoY) and the FY2025 annual result came in at $526.1 million, down 12.36% from the prior year.
• Assets Average rose to $509.3 million in Q1 2026 per ADPT's latest filing, from $501.7 million in the prior quarter.
• Over five years, Assets Average peaked at $890.8 million in Q1 2022 and troughed at $493.6 million in Q3 2025.
• A 5-year average of $668.8 million and a median of $640.7 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2026: Assets Average retreated 22.86% in 2024, then dropped 3.0% in 2026.
• Over 5 years, Assets Average stood at $870.4 million in 2022, then declined by 20.8% to $689.4 million in 2023, then dropped by 20.38% to $548.9 million in 2024, then retreated by 8.61% to $501.7 million in 2025, then increased by 1.53% to $509.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $509.3 million, $501.7 million, and $493.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.